19 / 21
PARP inhibitors as Therapy
How, When, Who and Why
1.
How?
§
Monotherapy as a new line of treatment
•
Olaparib : 300 mg/12
(only in the US)
•
Rucaparib : 600mg/12h( EU & USA)
2.
When ?
§
In the relapse setting
•
Olaparib: no suitable for further platinum therapy regardless platinum sensitivity
(only in the US)
•
Rucaparib: only sensitive relapse (unable to tolerate platinum therapy( EU))
3.
Who?
§
Olaparib: Only germline BRCA mut patients who have received at least 3 previous lines of therapy
(only in
the US)
§
Rucaparib: BRCA mut patients( germline and somatic) who have received at least 2 previous lines of
therapy